Tesamorelin Peptide: Clinical Research & Approved-Use Record
Disclaimer: All content on this site is an educational summary of public academic and industry research, compiled for informational reference only. It is not medical or laboratory advice. No treatment, health, or purchasing decisions should be made based solely on website content. This site does not sell peptides, does not link sellers, and does not endorse any vendor or any use of any compound.
Definition and core facts
tesamorelin peptide is a 44-residue synthetic analog of human growth hormone-releasing hormone (GHRH 1-44), differing from the native hormone by a trans-3-hexenoic acid group at the N-terminus — a modification that resists dipeptidyl peptidase cleavage and extends half-life. It is the approved contrast case of this cluster: FDA-approved (as Egrifta) for the reduction of excess abdominal fat in HIV-associated lipodystrophy, with a full regulatory dossier, label, and trial record.
The indication is deliberately narrow and label-defined. The approval rests on randomized trials in people with HIV-associated lipohypertrophy showing reductions in trunk fat measured by DEXA and CT, with discontinuation associated with fat re-accumulation. Nothing in the label extends the indication to cosmetic use, to non-HIV populations, or to any performance context — and off-market use of growth-hormone-releasing analogs appears in enforcement literature precisely because of that gap.
Structure and mechanism
Mechanistically, tesamorelin is a GHRH receptor agonist: it stimulates endogenous growth-hormone pulsatile release from the pituitary, with downstream IGF-1 elevation and lipolytic effects on visceral adipose. The pharmacology is the body's own axis, amplified by an N-terminal modification — the same degradation-avoidance design logic seen in the incretin analogs documented in the science pillar and in mt2 peptide's substitutions.
The 44-residue chain places tesamorelin at the small-protein end of the peptide size classes (see the definition page); its synthesis is standard Fmoc chemistry at the scale covered by the synthesis page, and its regulatory manufacturing sits in the CDMO tier documented on the bachem page.
How it is measured and used in research
The trial record is the page's core data: randomized, controlled trials in the indicated population, with imaging-quantified endpoints (trunk fat by DEXA/CT, visceral adipose tissue), metabolic secondary endpoints, and a defined adverse-event profile (injection-site reactions, arthralgias documented in labeling; glucose monitoring addressed in the label for diabetic patients). Published data demonstrates the approved endpoint; it does not support extrapolation beyond it — the distinction the whole site exists to maintain.
For comparison across the research-compound spectrum: bcp157 peptide (pre-clinical predominance) and mt2 peptide (unapproved everywhere) sit at the other end of the evidence ladder from tesamorelin. Reading the three together is the fastest way to understand what “tier” means in peptide evidence.
Research context and related pages
Label facts a researcher will want: daily subcutaneous administration of the approved product, ~44-residue chain with the trans-hexenoyl cap, GHRH-agonist pharmacology, narrow approved population, and monitoring provisions in labeling. The label itself is the source — this page summarizes it and does not replace it.
The hub is the peptide science & research pillar; the supply-tier context (why an approved peptide is not a research chemical) is on the vendor pillar.
How to use the data on this page
Step 1 — extract the parameters. Extract: sequence length and N-terminal modification, approved indication and population, trial endpoints (imaging-quantified), labeled adverse-event profile.
Step 2 — normalize before comparing. Normalize: never compare approved-population trial results with rodent-model claims from other peptides; the tiers do not mix.
Step 3 — grade the source. Grade: FDA label and approval record Tier 1; published trials Tier 1; enforcement and misuse literature Tier 2.
Parameter comparison
The tesamorelin record across the evidence spectrum.
| Element | Record | Tier |
|---|---|---|
| Structure | GHRH(1-44) analog, trans-3-hexenoic acid cap | Tier 1 |
| Mechanism | GHRH receptor agonist; GH/IGF-1 axis | Tier 1 |
| Approval | HIV-associated lipodystrophy (excess abdominal fat) | Tier 1 (label) |
| Endpoints | Trunk fat by DEXA/CT, visceral fat | Tier 1 (RCTs) |
| Scope limits | No non-HIV or cosmetic indication | Label-defined |
Table: The tesamorelin record across the evidence spectrum. — compiled from public regulatory and academic sources; verify against the original documents before use.
Frequently asked questions
What is tesamorelin peptide used for?
Tesamorelin is FDA-approved (Egrifta) for reducing excess abdominal fat in HIV-associated lipodystrophy, in adults with lipohypertrophy on antiretroviral therapy, as an adjunct to lifestyle measures. The approval does not extend to other populations or uses; the label's monitoring provisions govern approved use. This page summarizes the regulatory record and is not usage advice.
References
- FDA prescribing information for tesamorelin (Egrifta) — Tier 1 regulatory source.
- Published randomized trials of tesamorelin in HIV-associated lipodystrophy (Tier 1).
- GHRH structure-activity literature (N-terminal modification chemistry).